Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood tube study checks if device boosts healing cells

NCT ID NCT07041918

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a medical device called VACUSERA PRP Tube, which is used to make platelet-rich plasma (PRP) from a person's own blood. PRP is sometimes used to help healing. The study involved 194 healthy volunteers and measured how well the tube increased the concentration of platelets compared to whole blood. No treatment was given; it was only a performance check of the device.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

194 people

The number who actually took part.

Started

May 2025

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male or female volunteers between the ages of 18 and 60, as defined in the target population during screening,

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA Male or female volunteers between the ages of 18 and 60, as defined in the target population during screening, Body Mass Index (BMI) between 18 and 32 during screening, No pregnancy or risk of pregnancy for women, Willing to participate and provide written informed consent and comply with the study restrictions, Must not have participated in any clinical trial within 2 months prior to the start of the study, Must be able to communicate with the researcher or authorized personnel. EXCLUSION CRITERIA Platelet dysfunction syndrome, Critical thrombocytopenia, Hemodynamic instability, Septicemia, Local infection at the site of the procedure, Autoimmune diseases, History of chronic infections, Chronic liver pathology, Patients receiving anticoagulant/antiplatelet therapy, Use of NSAIDs (except for paracetamol) in the last 7-10 days, History of alcohol and/or drug addiction, Corticosteroid use, Fever or illness in the past week, Cancer (especially blood and bone cancers), Hemoglobin (HGB) levels below 10 g/dl or above 16.5 g/dl in men and 16 g/dl in women, Platelet count below 105/μl, Those under immunosuppressive therapy, Any condition or disease detected during the medical interview/physical examination that, in the opinion of the researcher or designated personnel, would make the volunteer unsuitable for the study, put them at unnecessary risk, or interfere with the volunteer's ability to complete the study, Clinically significant deviation from normal findings in the physical examination, including vital signs, Patients planning pregnancy or not using contraception, Patients using hormonal contraceptive methods to prevent pregnancy, Breastfeeding women, Poor venous access for blood sampling, Plasma or blood donation within the last 2 months, It is recommended to select patients who do not use tobacco products during the study, as it is considered that it may affect the product's performance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for No disease or condition is being studied are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical Point Hastanesi Klinik Araştırmalar Merkezi

    Izmir, Karşıyaka, 35575, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.